Nuclex therapy for patients with chronic hepatitis C
by Zenovii Y. Tkachuk; Valery M. Frolov; Yana A. Sotska; Oksana V. Kruglova
International Journal of Immunological Studies (IJIS), Vol. 1, No. 4, 2012

Abstract: The three-month treatment with Nuclex and α-2b IFN in the complex therapy of the main group of CHC patients resulted in a positive dynamics in the clinical and immunological indicators and improvement in the functional status of the liver. The reference group of the patients, which received only α-2b IFN, also showed the positive dynamics of the analysed indicators, although to a much smaller degree as compared to the main group. The viral loads in the main group patients substantially dropped: the majority of the patients from the main group (78.6%) after the end of the treatment had minimal levels of the viral loads ranging (150-499) × 10³, while in some of the patients (10.7%) the virus was not detected at all. In the reference group, the treatment outcome was 4.5 times less than in the main group. The obtained results to allow consider the application of Nuclex in the complex therapy of CHC patients.

Online publication date: Sat, 30-Aug-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Immunological Studies (IJIS):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com